

COLLABORATION WITH LEADING SINGAPORE HEALTHCARE GROUP TO DEVELOP NEW REGENERATIVE BONE & TISSUE PRODUCTS

Highlights:

- *Collaboration Agreement signed with SGX Catalist-listed healthcare group, Livingstone Health, to jointly develop new products for regenerating bone & tissue.*
- *Singapore-based Livingstone Health is a multidisciplinary healthcare provider with a network of 14 medical clinics located at various locations in Singapore.*
- *Both Companies will work together to identify and co-develop products that improve healing in the musculoskeletal segment, with two upcoming surgeries that will see Osteopore implants being used for orthopaedic applications for the first time in Singapore.*
- *The partnership forms part of Osteopore's strategy to not only develop new products, but also uncover new potential applications using its existing commercially available implants.*

20 June 2022: Osteopore Limited (ASX: OSX) ("Osteopore" or the "Company"), an Australian and Singapore based global leader in the manufacture of innovative regenerative implants that empower natural tissue regeneration, is pleased to announce it has signed a Collaboration Agreement with Livingstone Health Holding Limited ("Livingstone Health"), to jointly develop new applications and products for regenerating bone and tissue.

SGX Catalist-listed Livingstone Health is a Singapore-based multidisciplinary healthcare group, whose core competencies include Aesthetics & Wellness, Anaesthesiology & Pain Management, Family Medicine, Internal Medicine, and Orthopaedic Surgery. The Group has 19 medical doctors and healthcare professionals, practising at 14 medical clinics located throughout Singapore.

Under the Collaborative Agreement, Livingstone Health's highly experienced surgeons will work closely with Osteopore to jointly develop products, solutions and therapies for bone and tissue regeneration using Osteopore's bioresorbable implants. Osteopore's implants dissolve over time to leave only natural healthy bone, and have largely outperformed traditional implant methods in terms of design, post-surgery complications and associated long-term health care costs.

Surgeons from Livingstone Health will apply new and existing Osteopore implants in a clinical setting for orthopaedic procedures. The first being Osteomesh[®], a rigid yet flexible bioresorbable scaffold, which will be used for tendon repair, including rotator cuff and Achilles tendon. To date, Osteomesh[®] has been used in cranial (skull) and orbital (eye) reconstruction, as well as in rhinoplasty, as a cartilage support. The partnership with Livingstone Health will enable the expansion of the Osteomesh[®] in tendon repair, and this will be the first time the products are used for orthopaedic applications in Singapore.

The second is an entirely new Osteopore product, a synthetic fibular strut graft, which will be used for bone reconstruction in the upper and lower limbs. The synthetic fibular strut will reduce the need to harvest bone from the fibula (shin bone), avoiding additional procedures and associated complications.

Both of these procedures form part of Osteopore's strategy to not only develop new products, but also uncover new potential applications using its existing commercially available implants. This is a key step in expanding the commercial use of Osteopore's platform technology and will provide Osteopore with important patient data to further support regulatory clearances, market adoption and penetration in Singapore and beyond.

Dr. Wilson Tay, CEO of Livingstone Health, said, "It is an exciting partnership which puts Livingstone Health at the forefront of orthopaedic technology and is in line with the Group's commitment to providing holistic healthcare for our patients. We look forward to working closely with Osteopore to develop cutting-edge products that accelerate healing and reduce the risk of complications patients face post-surgery."

Mr. Mark Leong, Executive Chairman of Osteopore, said, "We are pleased to be collaborating with the Livingstone Health orthopaedic team and leverage their expertise to bring our proven tissue regeneration technology to their patients. We look forward to entering the orthopaedic space in Singapore having already successfully conducted several world-first orthopaedic surgeries in Australia, where our scaffolds helped regenerate a 36cm shin bone."

Additional Agreement Details

The Agreement is for a period of 36 months from 17 June 2022 unless earlier terminated in accordance with the terms of this Agreement. The Agreement contains standard termination provisions including termination in the event of material breach of obligations and liquidation. The terms of the Agreement do not contain binding minimum sales thresholds, however initial sales which are not expected to be material on the onset may be achieved by successful commercialisation of products. Additionally, the deployment of a commercially available 3D printer for the printing of anatomical models for enhanced clinician-patient engagement may result in service fees that are chargeable (on a case-by-case basis) are not expected to be material. This collaboration provides a framework in which clinical data may be collected to confirm the safety and performance of Osteopore devices in these new application areas. The Agreement also contains such other terms that are standard in agreements of this nature. The Company will update the market as further information becomes available.

Ownership of Project IP shall be assessed on a case-by-case basis. Where IP is assessed to be jointly developed, the Parties shall appoint either Osteopore or Livingstone as the lead party to undertake the filing, prosecution and maintenance of all applications for the registration of patents, trademarks, designs and copyrights (where applicable) for the protection of the Project IP within the Field in the joint names of Osteopore and Livingstone or their assignees.

This announcement has been approved for release by the Board of Osteopore.

For more information, please contact:

Mark Leong

Executive Chairman

Osteopore Limited

+65 9011 7009

Mark_Leong@osteopore.com

About Osteopore Limited

Osteopore Limited is an Australian and Singapore based medical technology company commercialising a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material. Osteopore's patent-protected scaffolds are made from proprietary polymer formulations that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing post-surgery complications commonly associated with permanent bone implants.

About Livingstone Health

Livingstone Health Holdings Limited. ("Livingstone Health" and together with its subsidiaries, the "Group") is a Singapore-based multidisciplinary healthcare group whose core competencies include Aesthetics & Wellness, Anaesthesiology & Pain Management, Family Medicine, Internal Medicine, and Orthopaedic Surgery.

The name "Livingstone" is inspired by the succulent plant Lithops, also known as "living stones". They symbolise the Group's resilience, growth and determination to be recognised as a trusted integrated healthcare provider for patients, as well as a centre of excellence of growth opportunities for medical professionals.

The Group has 19 medical doctors and healthcare professionals, practising at 14 medical clinics, one medical spa, one health screening center, and a Podiatry and Physio Clinic located at convenient and accessible locations throughout Singapore. It also provides healthcare consultancy design services within the region.

Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are, or may be, forward-looking statements. Such statements relate to

future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements depending on various factors.